Clozapine

Clozapine
Skeletal formula of clozapine
Stick-and-ball model of the clozapine molecule
Systematic (IUPAC) name
8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
Clinical data
Trade names Clozaril, FazaClo, Versacloz
AHFS/Drugs.com monograph
MedlinePlus a691001
Pregnancy
category
  • AU: C
  • US: B (No risk in non-human studies) [1]
Legal status
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 60 to 70%
Metabolism Liver, by several CYP isozymes
Biological half-life 6 to 26 hours (mean value 14.2 hours in steady state conditions)
Excretion 80% in metabolized state: 30% biliary and 50% kidney
Identifiers
CAS Number 5786-21-0 YesY
ATC code N05AH02
PubChem CID 2818
IUPHAR/BPS 38
DrugBank DB00363 YesY
ChemSpider 10442628 YesY
UNII J60AR2IKIC YesY
KEGG D00283 YesY
ChEBI CHEBI:3766 YesY
ChEMBL CHEMBL42 YesY
Chemical data
Formula C18H19ClN4
Molar mass 326.823 g/mol
Physical data
Melting point 183 °C (361 °F)
Solubility in water 0.1889[2] mg/mL (20 °C)
  (verify)

Clozapine, sold under the brand name Clozaril among others, is an atypical antipsychotic medication.[1] It is mainly used for schizophrenia that does not improve following the use of other antipsychotic medications. In those with schizophrenia and schizoaffective disorder it may decrease the rate of suicidal behavior.[1] It is possibly more effective than typical antipsychotics.[3] It is taken by mouth.[1]

Clozapine is associated with a relatively high risk of low white blood cells which may result in death. To decrease this risk it is recommended that the blood be regularly monitored.[1] Other serious risks include seizures, inflammation of the heart, high blood sugar levels, and in older people with psychosis as a result of dementia an increased risk of death.[1][4] Common side effects include drowsiness, dry mouth, low blood pressure, trouble seeing, and dizziness.[1] The potentially permanent movement disorder tardive dyskinesia occurs in about 5% of people.[4] Its mechanism of action is not entirely clear.[1]

Clozapine was discovered in the 1960s and began being used in healthcare in 1971. It was the first atypical antipsychotic.[5] It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.[6] It is available as a generic medication.[1] The wholesale cost is between 0.05 and 2.10 USD per day as of 2014.[7]

Medical uses

Clozapine is an atypical antipsychotic drug primarily used in people who are unresponsive to or intolerant of other antipsychotics.[8] This means that they have failed to respond satisfactorily to at least two different antipsychotics.[9] It has been shown to be more effective in reducing symptoms of schizophrenia than typical antipsychotics, with more pronounced effects in those who have responded poorly to other medication. The relapse rate is lower and patient acceptability is better.[8] There is some evidence clozapine may reduce propensity for substance abuse in schizophrenic patients.[10]

It may be better than other antipsychotics in people with both schizophrenia and Parkinson's.[11]

Clozapine is not recommended for the treatment of behavior problems in older adults with dementia.

Side effects

Clozapine may cause side effects. Some are serious and potentially fatal. Common side effects include constipation, bed-wetting, night-time drooling, muscle stiffness, sedation, tremors, orthostatic hypotension, hyperglycemia, and weight gain. The risk of developing extrapyramidal symptoms such as tardive dyskinesia is below that of typical antipsychotics; this may be due to clozapine's anticholinergic effects. Extrapyramidal symptoms may subside somewhat after a person switches from another antipsychotic to clozapine.[12]

Clozapine also carries five black box warnings, including warnings for agranulocytosis, CNS depression, leukopenia, neutropenia, seizure disorder, bone marrow suppression, dementia, hypotension, myocarditis, orthostatic hypotension (with or without syncope) and seizures.[13] Lowering of the seizure threshold may be dose related and slow initial titration of dose may decrease the risk for precipitating seizures. Slow titration of dosing may also decrease the risk for orthostatic hypotension and other adverse cardiovascular side effects.[14]

Many male patients have experienced cessation of ejaculation during orgasm as a side effect of clozapine, though this is not documented in official drug guides.[15]

However, many side-effects can be managed and do not necessarily warrant discontinuation.[16]

Agranulocytosis

Main article: Agranulocytosis

Clozapine carries a black box warning for drug-induced agranulocytosis. Without monitoring, agranulocytosis occurs in about 1% of patients who take clozapine during the first few months of treatment;[17] the risk of developing it is highest about three months into treatment, and decreases substantially thereafter, to less than 0.01% after one year.[18]

Clozapine induced agranulocytosis can be transient.[19]

Cardiac toxicity

Myocarditis is a sometimes fatal side effect of clozapine, which usually develops within the first month of commencement.[20] First manifestations of illness are fever which may be accompanied by symptoms associated with upper respiratory tract, gastrointestinal or urinary tract infection. Typically C-reactive protein (CRP) increases with the onset of fever and rises in the cardiac enzyme, troponin, occur up to 5 days later. Monitoring guidelines advise checking CRP and troponin at baseline and weekly for the first 4 weeks after clozapine initiation and observing the patient for signs and symptoms of illness.[21] Signs of cardiac failure are less common and may develop with the rise in troponin. A recent case-control study found that the risk of clozapine-induced myocarditis is increased with increasing rate of clozapine dose titration, increasing age and concomitant sodium valproate.[22]

Gastrointestinal hypomotility

Another underrecognized and potentially life-threatening side effect spectrum is gastrointestinal hypomotility, which may manifest as severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis. Monitoring of bowel function is recommended, as untreated cases are occasionally fatal.[23][24]

Hypersalivation

While clozapine is a muscarinic antagonist at the M1, M2, M3, and M5 receptors, clozapine is a full agonist at the M4 subset. Because M4 is highly expressed in the salivary gland, its M4 agonist activity is thought to be responsible for the hypersalivation.[25]

Central nervous system

CNS side effects include drowsiness, vertigo, headache, tremor, syncope, sleep disturbances, nightmares, restlessness, akinesia, agitation, seizures, rigidity, akathisia, confusion, fatigue, insomnia, hyperkinesia, weakness, lethargy, ataxia, slurred speech, depression, myoclonic jerks, and anxiety. Rarely seen are delusions, hallucinations, delirium, amnesia, libido increase or decrease, paranoia and irritability, abnormal EEG, worsening of psychosis, paresthesia, status epilepticus, and obsessive compulsive symptoms. Similar to other antipsychotics clozapine rarely has been known to cause neuroleptic malignant syndrome.[26]

Urinary incontinence

Clozapine is linked to urinary incontinence[27] though its appearance may be under-recognized.[28]

Withdrawal effects

Abrupt withdrawal may lead to cholinergic rebound effects, severe movement disorders as well as severe psychotic decompensation. It has been recommended that patients, families, and caregivers are aware of the symptoms and risks of abrupt withdrawal of clozapine. When discontinuing clozapine, gradual dose reduction is recommended to reduce the intensity of withdrawal effects.[29][30]

Weight gain and diabetes

In addition to hyperglycemia, significant weight gain is frequently experienced by patients treated with clozapine.[31] Impaired glucose metabolism and obesity have been shown to be constituents of the metabolic syndrome and may increase the risk of cardiovascular disease. The data suggest that clozapine may be more likely to cause adverse metabolic effects than some of the other atypical antipsychotics.[32] A study has established that olanzapine and clozapine disturb the metabolism by making the body take preferentially its energy from fat (instead of privileging carbohydrates). Levels of carbohydrates remaining high, the body develops insulin resistance (causing diabetes).[33]

Interactions

Fluvoxamine inhibits the metabolism of clozapine leading to significantly increased blood levels of clozapine.[34]

When carbamazepine is concurrently used with clozapine, it has been shown to decrease plasma levels of clozapine significantly thereby decreasing the beneficial effects of clozapine.[35][36] Patients should be monitored for “decreased therapeutic effects of clozapine if carbamazepine” is started or increased. If carbamazepine is discontinued or the dose of carbamazepine is decreased, therapeutic effects of clozapine should be monitored. The study recommends carbamazepine to not be used concurrently with clozapine due to increased risk of agranulocytosis.[37]

Published case reports have stated that the use of benzodiazepines and clozapine concomitantly can result in severe adverse reaction such as respiratory arrest, cardiac arrest and sudden death.[38]

Ciprofloxacin is an inhibitor of CYP1A2 and clozapine is a major CYP1A2 substrate. Randomized study reported elevation in clozapine concentration in schizophrenia subjects concurrently taking ciprofloxacin.[39] Thus, the prescribing information for clozapine recommends “reducing the dose of clozapine by one-third of original dose” when ciprofloxacin and other CYP1A2 inhibitors are added to therapy, but once ciprofloxacin is removed from therapy, it is recommended to return clozapine to original dose.[40]

Chemistry

Clozapine is a dibenzodiazepine that is structurally related to loxapine. It is slightly soluble in water, soluble in acetone, and highly soluble in chloroform. Its solubility in water is 188.9 mg/L (25 °C).[2] Its manufacturer, Novartis, claims a solubility of <0.01% in water (<100 mg/L).[41]

Mechanism of action

Clozapine is classified as an atypical antipsychotic drug because it binds to serotonin as well as dopamine receptors.[42]

Clozapine is a partial agonist[43] at the 5-HT1A subunit of the serotonin receptor, putatively improving depression, anxiety, and the negative cognitive symptoms associated with schizophrenia.[44]

A direct interaction of clozapine with the GABAB receptor has also been shown.[45] GABAB receptor-deficient mice exhibit increased extracellular dopamine levels and altered locomotor behaviour equivalent to that in schizophrenia animal models.[46] GABAB receptor agonists and positive allosteric modulators reduce the locomotor changes in these models.[47]

Clozapine induces the release of glutamate and D-serine, an agonist at the glycine site of the NMDA receptor, from astrocytes,[48] and reduces the expression of astrocytic glutamate transporters. These are direct effects that are also present in astrocyte cell cultures not containing neurons. Clozapine prevents impaired NMDA receptor expression caused by NMDA receptor antagonists.[49]

Binding Affinity (Ki [nM]) towards cloned human receptors unless otherwise specified[50]

Receptor/Transporter Protein Clozapine Norclozapine
SERT 1624 316.6
NET 3168 493.9
DAT >10,000 >10,000
5-HT1A 123.7 13.9
5-HT1B 519 406.8
5-HT1D 1356 476.2
5-HT2A 5.35 10.9
5-HT2B 8.37 2.8
5-HT2C 9.44 11.9
5-HT3 241 272.2
5-HT5A 3857 350.6
5-HT6 13.49 11.6
5-HT7 17.95 60.1
D1 266.25 14.3
D2 157 101.4
D3 269.08 193.5
D4 26.36 63.94
D5 255.33 283.6
α1A 1.62 104.8
α1B 7 85.2
α2A 37 137.6
α2B 26.5 95.1
α2C 6 117.7
β1 5000 6239
β2 1650 4725
M1 6.17 67.6
M2 36.67 414.5
M3 19.25 95.7
M4 15.33 169.9
M5 15.5 35.4
H1 1.13 3.4
H2 153 345.1
H3 >10,000 >10,000
H4 665 1028
δ-opioid 1000 (Mouse receptor) 127.9
μ-opioid 1000 (Rat receptor) >10,000
κ-opioid 1000 (Guinea pig receptor) >10,000
σ1 5000 (Guinea pig receptor) >10,000
σ2 - >10,000

Pharmacokinetics

N-desmethylclozapine (norclozapine), clozapine's chief active metabolite

The absorption of clozapine is almost complete, but the oral bioavailability is only 60 to 70% due to first-pass metabolism. The time to peak concentration after oral dosing is about 2.5 hours, and food does not appear to affect the bioavailability of clozapine. The elimination half-life of clozapine is about 14 hours at steady state conditions (varying with daily dose).

Clozapine is extensively metabolized in the liver, via the cytochrome P450 system, to polar metabolites suitable for elimination in the urine and feces. The major metabolite, norclozapine (desmethyl-clozapine), is pharmacologically active. The cytochrome P450 isoenzyme 1A2 is primarily responsible for clozapine metabolism, but 2C, 2D6, 2E1 and 3A3/4 appear to play roles as well. Agents that induce (e.g., cigarette smoke) or inhibit (e.g., theophylline, ciprofloxacin, fluvoxamine) CYP1A2 may increase or decrease, respectively, the metabolism of clozapine. For example, the induction of metabolism caused by smoking means that smokers require up to double the dose of clozapine compared with non-smokers to achieve an equivalent plasma concentration.[51]

Clozapine and norclozapine plasma levels may also be monitored, though they show a significant degree of variation and are higher in women and increase with age.[52] Monitoring of plasma levels of clozapine and norclozapine has been shown to be useful in assessment of compliance, metabolic status, prevention of toxicity, and in dose optimization.[51]

History

Clozapine was developed by Sandoz in 1961, and trials took place in 1972, when it was released in Switzerland and Austria as Leponex. Two years later it was released in West Germany, and Finland in 1975. Early testing was performed in the United States around the same time.[53] In 1975, after reports of agranulocytosis leading to death in some clozapine-treated patients, clozapine was voluntarily withdrawn by the manufacturer.[54] Clozapine fell out of favor for more than a decade. However, when studies demonstrated that clozapine was more effective against treatment-resistant schizophrenia than other antipsychotics, the FDA and health authorities in most other countries approved its use only for treatment-resistant schizophrenia, and required Restricted Distribution, a Patient Registry and regular hematological monitoring to detect granulocytopenia, before agranulocytosis develops. In December 2002, clozapine was approved in the US for reducing the risk of suicide in schizophrenic or schizoaffective patients judged to be at chronic risk for suicidal behavior.[55] In 2005 FDA approved criteria to allow reduced blood monitoring frequency.[56]

In 2015 the individual manufacturer Patient Registries were consolidated into a single shared Patient Registry administered by FDA.

See also

References

  1. 1 2 3 4 5 6 7 8 9 "Clozapine". The American Society of Health-System Pharmacists. Retrieved Dec 1, 2015.
  2. 1 2 Hopfinger A, Esposito EX, Llinas A, Glen RC, Goodman JM. (2009). "Findings of the Challenge To Predict Aqueous Solubility". Journal of Chemical Information and Modeling 49: 1–5. doi:10.1021/ci800436c. PMID 19117422.
  3. ↑ Essali, A; Al-Haj Haasan, N; Li, C; Rathbone, J (21 January 2009). "Clozapine versus typical neuroleptic medication for schizophrenia.". The Cochrane database of systematic reviews (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMID 19160174.
  4. 1 2 Hartling, L; Abou-Setta, AM; Dursun, S; Mousavi, SS; Pasichnyk, D; Newton, AS (2 October 2012). "Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.". Annals of internal medicine 157 (7): 498–511. doi:10.7326/0003-4819-157-7-201210020-00525. PMID 22893011.
  5. ↑ Corey, edited by Jie Jack Li, E.J. (2013). Drug discovery practices, processes, and perspectives. Hoboken, N.J.: John Wiley & Sons. p. 248. ISBN 9781118354469.
  6. ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  7. ↑ "Clozapine". International Drug Price Indicator Guide. Retrieved 2 December 2015.
  8. 1 2 Wahlbeck K, Cheine M, Essali MA (2007). Wahlbeck K, ed. "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews (John Wiley and Sons, Ltd.) (2): CD000059. doi:10.1002/14651858.CD000059. PMID 10796289.
  9. ↑ Meltzer HY (1997). "Treatment-resistant schizophrenia--the role of clozapine". Current Medical Research and Opinion 14 (1): 1–20. doi:10.1185/03007999709113338. PMID 9524789.
  10. ↑ Lee M, Dickson RA, Campbell M, Oliphant J, Gretton H, Dalby JT. (1998). "Clozapine and substance abuse in patients with schizophrenia". Canadian Journal of Psychiatry 43: 855–856.
  11. ↑ "How would you treat someone who has both schizophrenia and Parkinson's disease?".
  12. ↑ "Clozapine".
  13. ↑ http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=142&sec=monadve
  14. ↑ "Clozapine".
  15. ↑ Baggaley M (Apr 2008). "Sexual dysfunction in schizophrenia: focus on recent evidence". Human Psychopharmacology 23 (3): 201–209. doi:10.1002/hup.924. PMID 18338766.
  16. ↑ Nielsen J, Correll CU, Manu P, Kane JM (Jun 2013). "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?". The Journal of Clinical Psychiatry 74 (6): 603–13. doi:10.4088/JCP.12r08064. PMID 23842012.
  17. ↑ Baldessarini, Ross J.; Frank I. Tarazi (2006). "Pharmacotherapy of Psychosis and Maa". In Laurence Brunton, John Lazo, Keith Parker (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. ISBN 978-0-07-142280-2. OCLC 150149056.
  18. ↑ Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (Jul 1993). "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States". The New England Journal of Medicine 329 (3): 162–7. doi:10.1056/NEJM199307153290303. PMID 8515788. Free full text with registration
  19. ↑ Midbari Y, Ebert T, Kosov I, Kotler M, Weizman A, Ram A (Oct 2013). "Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review". Journal of Child and Adolescent Psychopharmacology 23 (8): 516–21. doi:10.1089/cap.2013.0050. PMID 24111981.
  20. ↑ Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J (2007). "Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003". Drug Safety 30 (1): 47–57. doi:10.2165/00002018-200730010-00005. PMID 17194170.
  21. ↑ Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (Jun 2011). "A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls". The Australian and New Zealand Journal of Psychiatry 45 (6): 458–465. doi:10.3109/00048674.2011.572852. PMID 21524186.
  22. ↑ Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ (Nov 2012). "Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study". Schizophrenia Research 141 (2-3): 173–8. doi:10.1016/j.schres.2012.08.018. PMID 23010488.
  23. ↑ Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M (May 2008). "Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases". The Journal of Clinical Psychiatry 69 (5): 759–768. doi:10.4088/JCP.v69n0509. PMID 18452342.
  24. ↑ Townsend G, Curtis D (2006). "Case report: rapidly fatal bowel ischaemia on clozapine treatment". BMC Psychiatry 6 (1): 43. doi:10.1186/1471-244X-6-43. PMC 1621059. PMID 17052340.
  25. ↑ http://www.medscape.com/viewarticle/409612_2
  26. ↑ rxlist.com / Clozapine side effects
  27. ↑ Raja M (Jul 2011). "Clozapine safety, 35 years later". Current Drug Safety 6 (3): 164–184. doi:10.2174/157488611797579230. PMID 22122392.
  28. ↑ Barnes TR, Drake MJ, Paton C (Jan 2012). "Nocturnal enuresis with antipsychotic medication". The British Journal of Psychiatry 200 (1): 7–9. doi:10.1192/bjp.bp.111.095737. PMID 22215862.
  29. ↑ Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR (Sep 1998). "Clozapine withdrawal-emergent dystonias and dyskinesias: a case series". The Journal of Clinical Psychiatry 59 (9): 472–7. doi:10.4088/JCP.v59n0906. PMID 9771818.
  30. ↑ Szafrański T, Gmurkowski K (1999). "[Clozapine withdrawal. A review]". Psychiatria Polska 33 (1): 51–67. PMID 10786215.
  31. ↑ Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (Jun 1999). "Novel antipsychotics: comparison of weight gain liabilities". The Journal of Clinical Psychiatry 60 (6): 358–63. doi:10.4088/JCP.v60n0602. PMID 10401912.
  32. ↑ Nasrallah HA (Jan 2008). "Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles". Molecular Psychiatry 13 (1): 27–35. doi:10.1038/sj.mp.4002066. PMID 17848919.
  33. ↑ Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, Breazeale S, Elich TD, Lang CH, Lynch CJ (Jan 2012). "Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents". Schizophrenia Bulletin 38 (1): 153–166. doi:10.1093/schbul/sbq053. PMC 3245588. PMID 20494946.
  34. ↑ Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (Dec 1997). "Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence". Clinical Pharmacokinetics 33 (6): 454–71. doi:10.2165/00003088-199733060-00004. PMID 9435993.
  35. ↑ Tiihonen J, Vartiainen H, Hakola P (Jan 1995). "Carbamazepine-induced changes in plasma levels of neuroleptics". Pharmacopsychiatry 28 (1): 26–28. doi:10.1055/s-2007-979584. PMID 7746842.
  36. ↑ Besag, FM; Berry, D (2006). "Interactions between antiepileptic and antipsychotic drug". Drug Saf 29 (2): 95–118. doi:10.2165/00002018-200629020-00001.
  37. ↑ Jerling, M; Lindstrom, L; Bondesson, U; et al. (1994). ", "Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence From a Therapeutic Drug Monitoring Service". Ther Drug Monit 16 (4): 368–74. doi:10.1097/00007691-199408000-00006.
  38. ↑ Bitter R, Demler TL, Opler L (Sep 2008). "Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review". Journal of Psychiatric Practice 14 (5): 265–70. doi:10.1097/01.pra.0000336753.11943.7c. PMID 18832957.
  39. ↑ Raaska K, Neuvonen PJ (Nov 2000). "Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia". European Journal of Clinical Pharmacology 56 (8): 585–9. doi:10.1007/s002280000192. PMID 11151749.
  40. ↑ Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2014.
  41. ↑ Novartis Pharmaceuticals (April 2006). "Prescribing Information" (PDF). Novartis Pharmaceuticals. p. 36. Retrieved 2007-06-29.
  42. ↑ Naheed M, Green B (2001). "Focus on clozapine". Current Medical Research and Opinion 17 (3): 223–9. doi:10.1185/0300799039117069. PMID 11900316.
  43. ↑ http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2818
  44. ↑ Robinson DS (2007). "CNS Receptor Partial Agonists: A New Approach to Drug Discovery". Primary Psychiatry 14 (8): 22–24.
  45. ↑ Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, Snead OC (Sep 2011). "Evidence that clozapine directly interacts on the GABAB receptor". NeuroReport 22 (13): 637–41. doi:10.1097/WNR.0b013e328349739b. PMID 21753741.
  46. ↑ Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, Waldmeier P, Kaupmann K, Pévet P, Bettler B (May 2006). "Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice". Journal of Neurochemistry 97 (4): 979–91. doi:10.1111/j.1471-4159.2006.03806.x. PMID 16606363.
  47. ↑ Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A (Jul 2011). "The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice". British Journal of Pharmacology 163 (5): 1034–47. doi:10.1111/j.1476-5381.2011.01301.x. PMC 3130949. PMID 21371011.
  48. ↑ Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M (Mar 2012). "Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes". British Journal of Pharmacology 165 (5): 1543–55. doi:10.1111/j.1476-5381.2011.01638.x. PMC 3372736. PMID 21880034.
  49. ↑ Xi D, Li YC, Snyder MA, Gao RY, Adelman AE, Zhang W, Shumsky JS, Gao WJ (May 2011). "Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex". Neuropsychopharmacology 36 (6): 1260–74. doi:10.1038/npp.2011.12. PMC 3079418. PMID 21326193.
  50. ↑ Roth, BL; Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 2013-10-10 from http://pdsp.med.unc.edu/pdsp.php.
  51. 1 2 Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (Feb 2004). "Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients". Journal of Clinical Psychopharmacology 24 (1): 70–8. doi:10.1097/01.jcp.0000106221.36344.4d. PMID 14709950.
  52. ↑ Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (Jan 1999). "Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics". The Journal of Clinical Psychiatry 60 (1): 36–40. doi:10.4088/JCP.v60n0108. PMID 10074876.
  53. ↑ Crilly J (Mar 2007). "The history of clozapine and its emergence in the US market: a review and analysis". History of Psychiatry 18 (1): 39–60. doi:10.1177/0957154X07070335. PMID 17580753.
  54. ↑ Healy, David (2004). The Creation of Psychopharmacology. Cambridge: Harvard University Press. pp. 238–42. ISBN 0-674-01599-1.
  55. ↑ "Supplemental NDA Approval Letter for Clozaril, NDA 19-758 / S-047" (PDF). United States Food and Drug Administration. December 18, 2002. Archived from the original on November 23, 1012. Retrieved November 23, 2012.
  56. ↑ http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/019758s054ltr.pdf

Further reading

External links

This article is issued from Wikipedia - version of the Friday, January 29, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.